Author: admin

Integral Molecular Launches Measles Reporter Virus Particles to Accelerate Research for Therapeutics

Philadelphia—Integral Molecular, the industry leader in providing reporter viruses to the vaccine industry, announces the launch of Measles Reporter Virus Particles (RVPs), expanding its […]

Integral Molecular Celebrates 25 Years of Advancing Drug Discovery as a Cornerstone of Philadelphia’s Biotech Community

Philadelphia— Integral Molecular, a founding member of Philadelphia’s biotechnology community, celebrates its 25th anniversary by bringing together its expertise in antibody discovery, protein engineering, […]

Inside the MPA Specificity Screen: From Assay Setup to Validated Off-Target

This article describes how a test article moves from initial setup through validated, quantified results, the advantages of flow cytometry detection, and why a […]

Beyond the Membrane: Secreted Proteins and Comprehensive Specificity Testing

Soluble, secreted proteins circulate through blood and tissues and can also be off-target binders, with consequences for both safety and pharmacokinetics. The Secreted Proteome […]

How We Built a Human Protein Library for Biotherapeutic Safety Screening

Specificity testing is ultimately a patient safety question: does this antibody bind only what it’s supposed to? Answering it requires a library that represents […]

Integral Molecular Earns Back-to-Back Top Workplace Honors from The Philadelphia Inquirer

Philadelphia – Integral Molecular, a founding member of Philadelphia’s biotechnology community, has again been named a Top Workplace by The Philadelphia Inquirer. The honor […]

The Consequences of Off-Target Binding Are Real. So Are the Solutions.

Off-target binding doesn’t always cause harm—but when it goes undetected, the consequences can be serious. Published case studies document off-target interactions that caused adverse […]

1 in 3 Antibody Drug Candidates Bind Off-Targets. Here’s What That Means.

In this article: How common is off-target binding, really? Does polyspecificity persist into late-stage clinical development? Why can’t you predict off-targets from sequence analysis […]

Webinar Presented by Integral Molecular and The Antibody Society – 100+ Undruggable Targets Unlocked Through Parallel MAb Engineering

Thursday, June 25, 2026 11 am EDT View the recording Many high value therapeutic targets, particularly multipass membrane proteins, remain untapped due to technical […]